Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OVID | US
-0.01
-0.85%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.17
1.17
1.18
1.13
Ovid Therapeutics Inc. a biopharmaceutical company engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat a novel cholesterol 24 hydroxylase inhibitor which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329 a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350 a small molecule direct activator of the KCC2 transporter which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815 currently under preclinical stage that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825 currently under preclinical stage which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882 currently under preclinical stage a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx AstraZeneca AB H. Lundbeck A/S and Northwestern University as well as Marinus Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in New York New York.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
38.2%1 month
58.9%3 months
72.8%6 months
131.6%-
1.79
0.92
0.18
0.14
-0.69
35.29
-
-65.78M
83.04M
83.04M
-
-11.08K
-
125.30
-29.81
4.10
1.08
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.16
Range1M
0.17
Range3M
0.50
Rel. volume
0.69
Price X volume
97.97K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
InflaRx N.V | IFRX | Biotechnology | 1.55 | 91.27M | 2.65% | n/a | 0.00% |
Tiziana Life Sciences PLC | TLSA | Biotechnology | 0.896 | 90.96M | 1.82% | n/a | 0.00% |
CytomX Therapeutics Inc | CTMX | Biotechnology | 1.16 | 90.62M | -1.69% | 7.67 | -37.61% |
Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 2.05 | 89.59M | -0.49% | n/a | 35.26% |
BioAtla Inc. | BCAB | Biotechnology | 1.85 | 89.42M | -5.61% | n/a | 5.30% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.33 | 89.16M | -2.92% | n/a | 0.73% |
MediciNova Inc | MNOV | Biotechnology | 1.805 | 88.53M | -2.43% | n/a | 0.86% |
Clearside Biomedical Inc | CLSD | Biotechnology | 1.15 | 85.96M | 2.68% | n/a | -168.27% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.43 | 83.95M | 0.56% | n/a | 167.26% |
PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.6 | 83.54M | 0.00% | n/a | 6.06% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.35 | 89.85M | 0.07% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.69 | 0.53 | Cheaper |
Ent. to Revenue | 35.29 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.92 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 72.81 | 72.92 | Par |
Debt to Equity | 0.18 | -1.24 | Expensive |
Debt to Assets | 0.14 | 0.25 | Cheaper |
Market Cap | 83.04M | 3.78B | Emerging |